Drug Trial Radar · NCT03287791
A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea
Last checked: Nov 19, 2026Latest source record: Jul 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
924
Actual
Start
Jul 19, 2016
Primary completion
Jun 22, 2017
Study completion Jun 22, 2017
Sponsor
- Lead sponsor
- Actavis Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study were to compare the safety and efficacy profiles of a generic Azelaic Acid Foam, 15% to the reference listed Finacea® (azelaic acid) Foam, 15% and to demonstrate therapeutic equivalence and safety of the two active foams in the treatment of moderate facial rosacea, and to demonstrate superiority of the Reference and Test products over the Vehicle.
Conditions
- Rosacea
Interventions
Generic Azelaic Acid FoamDrug
Topical foam, generic formulation of the brand product.
Finacea® (Azelaic Acid) FoamDrug
Topical foam, brand product.
Vehicle FoamDrug
Topical foam, placebo. Has no active ingredient.
CleanserOther
A mild cleanser provided to participants, so they can wash their face prior to applying the study drug.
SunscreenOther
Sunscreen provided to participants, so they can apply it to their face when outdoors.
TowelOther
A soft towel provided to participants, so they can pat their face dry after washing and prior to applying the study drug.
Moisturizing LotionOther
Moisturizing lotion provided to participants, so they can apply it to their face, as needed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in the Inflammatory Lesions (Papules and Pustules) Counts at Week 12Time frame: Baseline, 12 weeks
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Investigative Site 2
Encino, California
Investigative Site 10
La Mesa, California
Investigative Site 19
Brandon, Florida
Investigative Site 1
Hialeah, Florida
Investigative Site 9
Hialeah, Florida
Investigative Site 23
Lauderdale Lakes, Florida
Investigative Site 11
Miami, Florida
Investigative Site 15
Miami, Florida
Investigative Site 20
Miami, Florida
Investigative Site 12
Miramar, Florida
Investigative Site 25
Ocala, Florida
Investigative Site 22
Pembroke Pines, Florida
Investigative Site 18
Tampa, Florida
Investigative Site 16
Savannah, Georgia
Investigative Site 14
Plainfield, Indiana
Investigative Site 13
Wichita, Kansas
Investigative Site 6
New Orleans, Louisiana
Investigative Site 17
Omaha, Nebraska
Investigative Site 8
High Point, North Carolina
Investigative Site 3
Cincinnati, Ohio
Investigative Site 21
Philadelphia, Pennsylvania
Investigative Site 4
Dallas, Texas
Investigative Site 26
El Paso, Texas
Investigative Site 7
New Braunfels, Texas
Investigative Site 5
Norfolk, Virginia
Investigative Site 24
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.